Press release
Disguised Protein May Be A New Target For Cancer Immunotherapy
Researchers at the Francis Crick Institute have identified a protein that helps tumors evade the immune system and, in certain types of cancers, is linked to a poorer chance of survival. The protein could become a target for future cancer treatments.A crucial part of the immune system's response to cancer is a group of white blood cells, called CD8+ T-cells, which kill tumor cells. Before they launch their anti-tumor response, these cells must be told who to attack by another immune cell, called a dendritic cell.
In their study, published in Cell today (2 June), the scientists identified a protein that is present in blood plasma and is also secreted by cancer cells, secreted gelsolin, which interferes with this relay process by blocking a receptor inside dendritic cells. With no instruction passed to the T-cells, the tumors avoid their killer response.
The team analyzed clinical data and samples from cancer patients with 10 different types of the disease and found that individuals with liver, head and neck and stomach cancers, who have lower levels of this protein in their tumors had higher chances of survival.
They also found that blocking the action of this protein in mice with cancer increased their response to treatments including checkpoint inhibitors, a major immunotherapy.
This work builds on the team's research into dendritic cell biology. These cells absorb debris from dead cancer cells and hold them internally in pockets called phagosomes. Binding to a protein on the debris, F-actin, triggers these pockets to burst, releasing the debris into the cell where they can be processed and moved to the surface to signal the presence of a tumor to nearby T-cells.
When the researchers examined the activity of secreted gelsolin, they found the protein outcompetes a key dendritic cell receptor, blocking its ability to bind to F-actin and therefore the ability of the dendritic cells to initiate a T-cell response.
"Dendritic cells play a vital role in the immune system and our body's response to cancer," says Evangelos Giampazolias, author and postdoc in the Immunobiology Laboratory at the Crick. "Understanding this process in more detail will enable us to identify how cancers are able to hide and how we might remove their disguise."
"Reducing levels of this protein will help alleviate the competition for binding to F-actin and allow dendritic cells to communicate their vital message."
The researchers will continue this work, trying to develop a potential therapy that targets the secreted gelsolin in the tumor without affecting the activity of this protein in other parts of the body.
As a well-known manufacturer in China, Huateng Pharma is a professional pharmaceutical intermediates supplier with a 34000m2 industrial park and a 5000m2 R&D base. We are able to provide the services of Anti-Cancer intermediates’ process development and scale-up production with capacities varying from gram to kilograms and multi tons.
Hunan Huateng Pharmaceutical Co. Ltd.
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818
Website: https://en.huatengsci.com
Email: sales@huatengusa.com
Human Huateng Pharmaceutical Co., Ltd. is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on. Huateng Pharma is committed to providing cost-effective pharmaceutical products and services to customers around the world with the belief of “Strive for the Human Health".
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Disguised Protein May Be A New Target For Cancer Immunotherapy here
News-ID: 2322691 • Views: …
More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Supplies Minoxidil Intermediate 2,4-Diamino-6-chloropyrimidine (C …
Minoxidil was first introduced by Upjohn Company of the United States, and was first used as an oral drug for the treatment of refractory hypertension in the 1970s. In later clinical applications, doctors observed hair regrowth and generalized excessive hair in balding patients, which led to the development of minoxidil preparations.
Minoxidil can increase local blood supply, stimulate the proliferation and differentiation of hair follicle epithelial cells, so as to promote…

Huateng Pharma Supplies Anti-diabetic API Intermediates With Huge Stock
Diabetes is a serious chronic disease characterized by elevated blood sugar concentrations associated with the effects of abnormal beta cell biology on insulin action. Diabetes occurs when the pancreas does not produce enough insulin or the body does not use the insulin it does produce efficiently.
The most common forms of diabetes are type 1 diabetes and type 2 diabetes. Type 1 diabetes is characterized by insufficient insulin production and…

Huateng Pharma Supplies Some Intermediates of CDK4/6 Inhibitors for Treatment of …
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer - that is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally.
The majority…

ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…